Oestrogen receptor status is useful for assessing the likelihood of response to endocrine therapy in advanced breast cancer (Jensen et al., 1971; McGuire et al., 1975; Roberts et al., 1978) and may also serve as a prognostic index in early disease (Clark & McGuire, 1983; Knight et al., 1977; Nicholson et al., 1981) . In general terms, about 55% of receptor-positive tumours will respond to endocrine therapy whereas only 5% of receptor-negative tumours will do so (Hawkins et al., 1980) . It is well established that oestrogen receptor level is a function of tumour cellularity (Masters et al., 1978; Hawkins et al., 1981) Oestrogen receptor estimation was carried out by saturation analysis of homogenised tumour with separation of free and bound hormone by dextran-coated charcoal adsorption (Hawkins et al., 1975 (Hawkins et al., ,1981 . The dissociation constant of binding and the receptor concentration were calculated by Scatchard analysis (Scatchard, 1949) Overall, 512 tissues from breast cancer patients were sent for oestrogen receptor estimation. These comprised 472 assumed primary tumours, 10 assumed secondary deposits, and 30 clinically involved lymph nodes. In all cases, the patients from whom these tissues were removed had breast cancer proven on formal histology. In 15 instances, receptor assay was not performed. This was because at reception, macroscopically the tissue appeared unlikely to contain tumour and assay had been delayed until the result of formal and control histology examinations were available; for these 15 tissues it was shown that no tumour was present and assay was therefore unwarranted. Of the remaining 497 tissues, 131 (26%) were oestrogen receptor-negative, and, of these, 32 (24%) were regarded as histologically unsatisfactory; when the latter were excluded, the oestrogen receptor-negative rate was reduced from 26% (131/497) to 21% (99/465). The breakdown of oestrogen receptor-negative tissues is given in Table I : 22% of 'primary tumours' and 50% of 'metastases' in lymph nodes were histologically unsatisfactory.
This study demonstrates that histological confirmation of suspected tumour tissue must be carried out on a section from the actual specimen which is to be used for receptor estimation if false negative results are to be avoided. It is not sufficient to rely on microscopic examination of a separate, albeit adjacent, piece of tissue, as macroscopic appearances can be misleading. This is particularly true of the clinically involved lymph node, even when it has been excised and bisected by an experienced surgeon.
No criticism is levelled at the pathologists, as it is their duty to obtain an adequate sample of any tumour in order to allow thorough histological scrutiny. However, the biochemist who is to perform receptor assays may, of necessity, be left with a small portion of tissue, especially if other research interests are involved. We therefore believe that it is mandatory that he carries out his own histological checks, preferably aided by an experienced pathologist. Despite the value of this second or control histological check in assessing the adequacy/otherwise of the specimen used for biochemical assays of receptor activity, this procedure still suffers from some deficiencies. It must be noted that no unsatisfactory Totaladditional examination of the control histology was carried out for the receptor-positives. Furthermore, in view of the heterogeneity of breast tumours, removal and assessment of the control section from one face of the receptor specimen, whilst it represents an improvement over no histological check, does not necessarily reflect accurately the tumour content of the entire specimen. There is no completely satisfactory solution to this problem, though Van Netten et al. (1986) using a microsample technique, and Underwood et al. (1986) , using 40,um frozen sections, have reported methods for more accurately analysing receptor content in relation to morphology. It is now possible to detect the oestrogen receptor using both immunohistochemical techniques (ERICA) on frozen sections of tissue (King et al., 1983; Hawkins et al., 1986) , and immunoassays (EIA) on fine needle aspirates of tumour (Magdelenat, 1986) . These methods do not rely on radioligand binding and should be applicable to smaller samples of tissue for which the relevant histological check will be readily available, obviating the problems of false negatives due to inadequate specimens. However, immunohistochemistry may prove difficult to quantify accurately and the enzymimmunoassay on fine needle aspirates is not yet widely established. It seems likely, therefore, that for some time to come, biochemical assays (radioligand-binding or EIA) will still be performed on excised solid tumour specimens; for these a careful histological check will remain important.
In conclusion, 'control histology', although only a crude guide to the tumour content of the actual specimen used for assay, is, for the present, a vital step in eliminating false negative results for oestrogen receptor assays.
